venglustat (GZ402671) / Sanofi - LARVOL DELTA

Inhibiting UGCG prevents PRV infection by decreasing lysosome-associated autophage. (PubMed, Int J Biol Macromol) - "Finally, through in vivo evaluation, this study revealed that UGCG inhibitors, Eliglustat hemitartrate and Ibiglustat, hold promise as potential therapeutics for the treatment of PRV infection. In summary, this study preliminarily elucidates the impact of UGCG on PRV infection and its associated molecular mechanisms, suggesting UGCG could serve as a potential novel target for the prevention and treatment of viral diseases such as PRV."

Journal • Infectious Disease • Metabolic Disorders

LEAP2MONO: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (clinicaltrials.gov) - P3 | N=43 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Pediatrics • Type 1 Gaucher Disease • GBA

2024 Update of the TSOC Expert Consensus of Fabry Disease. (PubMed, Acta Cardiol Sin) - "Recent advances in pharmacological approach including enzyme replacement therapy (agalsidase alfa or beta), oral chaperone therapy (migalastat), and substrate reduction therapy (venglustat) aim to prevent from irreversible organ damage. Genotype- and gender-based monitoring of treatment effects through biomarker (Lyso-Gb3), renal assessment, and cardiac responses using advanced imaging modalities are key steps to optimizing patient care in FD."

Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cognitive Disorders • Congestive Heart Failure • Fabry Disease • Fibrosis • Genetic Disorders • Heart Failure • Immunology • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases

Targeting sphingolipid metabolism in chronic lymphocytic leukemia. (PubMed, Clin Exp Med) - "To evaluate the therapeutic potential of inhibiting GluCer synthesis, we genetically repressed the UGCG pathway using in vitro models of leukemic B cells, in addition to UGCG pharmacological inhibition with approved drugs such as eliglustat and ibiglustat, both individually and in combination with ibrutinib, assessed in cell models and primary CLL patient cells. Inhibitors that target alternative pathways within sphingolipid metabolism, like sphingosine kinases inhibitor SKI-II, also demonstrated promising therapeutic effects both alone and when used in combination with ibrutinib, reinforcing the oncogenic impact of sphingolipids in CLL cells. Targeting sphingolipid metabolism, especially the UGCG pathway, represents a promising therapeutic strategy and as a combination therapy for potential treatment of CLL patients, warranting further investigation."

Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology

PERIDOT: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease (clinicaltrials.gov) - P3 | N=114 | Recruiting | Sponsor: Sanofi | Trial completion date: Jul 2026 ➔ Oct 2025

Trial completion date • Fabry Disease • Genetic Disorders • Pain

Decreasing ganglioside synthesis delays motor and cognitive symptom onset in Spg11 knockout mice. (PubMed, Neurobiol Dis) - "Venglustat had similar effect on cultured human SPG11 neurons. In conclusion, this work identifies the first disease-modifying therapeutic strategy in SPG11, and provides data supporting its relevance for therapeutic testing in SPG11 patients."

Journal • Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Cognitive Disorders • Genetic Disorders • NEFL

Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP). (PubMed, Adv Ther) - P2 | "Outcomes from this study provide insights into GD3 symptoms and the early signaling of changes reported during venglustat therapy."

Journal • P2 data • Ataxia • CNS Disorders • Dystonia • Epilepsy • Gaucher Disease • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Movement Disorders • Ophthalmology • Rare Diseases

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Sanofi

New P1 trial

A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Sanofi

New P1 trial

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Genzyme, a Sanofi Company

New P1 trial

Humanistic Burden of Fabry Disease and Associated Utility Values (ISPOR 2024) - " We conducted an SLR in May 2022 (updated April 2023) to identify studies reporting humanistic burden and utility data in patients with FD who are either untreated or treated with enzyme replacement therapy (ERT) (pegunigalsidase alfa, agalsidase alfa, agalsidase beta), migalastat, venglustat, and lucerastat. The studies identified in this SLR add to our understanding of the humanistic burden of FD since almost 10 years ago. The results suggest utility values increase with ERT treatment, but patient burden has remained stable over time. Long-term data with existing therapies may provide additional insights on outcomes including pain, disease severity, and quality of life."

Fabry Disease • Fatigue • Gastrointestinal Disorder • Genetic Disorders • Pain

CARACTERIZACIÓN CLÍNICA Y EPIDEMIOLÓGICA DE LA ENFERMEDAD RENAL POLIQUÍSTICA EN PACIENTES ATENDIDOS EN UN CENTRO DE REFERENCIA DE CUARTO NIVEL DEL CARIBE COLOMBIANO DURANTE EL PERIODO 2008-2022 (ISN-WCN 2024) - "Los pacientes que presentan una progresión rápida de esta patología se benefician del antagonista del receptor V2 de la vasopresina Tolvaptan, único aprobado hasta el momento por la FDA (34)(35). Se encuentran en investigación moléculas como lixivaptan, venglustat, bardoxolona, tesevatinib, RGLS4326 (oligonucleótido inhibidor de microARN miR-17), GLPG2737 (corrector regulador de conductancia transmembrana de fibrosis quística), los cuales han venido demostrando efectos benéficos potenciales (36)(37)(38)(39). Otros medicamentos como everolimus ha evitado la progresión del volumen renal, pero no evitó la progresión de la enfermedad (40)... La ERP es una patología sistémica de relevancia importante debido al gran impacto que puede producir al deteriorar la salud de la persona comprometida, puede cursar desde estados asintomáticos a casos donde la función renal esta severamente deteriorada y por..."

Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology • MIR17 • PKD1 • PRKD1

Targeting protein N-terminal methyltransferases 1 for muscle regeneration (ACS-Sp 2024) - "The active inhibitor and negative control would serve as valuable tools to examine the physiological and pharmacological functions of NTMT1 catalytic activity. Additionally, this is the first disclosure of NTMT1 as a new molecular target of venglustat and a promising target for muscle regeneration."

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Sanofi | Recruiting ➔ Completed

Trial completion • Hepatology

Venglustat in GBA1-related Parkinson's disease. (PubMed, Lancet Neurol) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Venglustat in GBA1-related Parkinson's disease - Authors' reply. (PubMed, Lancet Neurol) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

CARAT: A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Sanofi | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Fabry Disease • Genetic Disorders

LEAP2MONO: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (clinicaltrials.gov) - P3 | N=40 | Recruiting | Sponsor: Sanofi | Trial completion date: Jan 2026 ➔ Oct 2026 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Pediatrics • Type 1 Gaucher Disease • GBA

LEAP2MONO: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (clinicaltrials.gov) - P3 | N=40 | Recruiting | Sponsor: Sanofi | Trial primary completion date: Aug 2024 ➔ Dec 2024

Trial primary completion date • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Pediatrics • Type 1 Gaucher Disease • GBA

CARAT: A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Sanofi | Trial completion date: Jan 2027 ➔ Jul 2027

Trial completion date • Fabry Disease • Genetic Disorders

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Sanofi | Trial completion date: Aug 2023 ➔ Dec 2023 | Trial primary completion date: Aug 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Hepatology

Safety and tolerability of pegunigalsidase alfa: Insights from a single site experience from the Expanded Access Program in the United States (SSIEM 2023) - P=N/A | "The enrollment reasons included poor tolerability of agalsidase beta (AB), disease progression on AB, and worsening of proteinuria on migalastat...One ERT-naïve male with classic FD enrolled due to poor tolerability with venglustat and withdrew after experiencing a serious adverse event (SAE) of hypersensitivity reaction with the third PA infusion (antidrug antibody [ADA]-negative at baseline [BL])... PA is a novel ERT that is well tolerated in patients with FD. While healthcare providers should remain vigilant for possible hypersensitivity reactions, PA may offer the benefit of reduced infusion duration and lower premedication burden for some patients with poor tolerability with other ERTs."

Clinical • Cardiovascular • Fabry Disease • Genetic Disorders • Immunology • Movement Disorders • Renal Disease • Transplantation • Ventricular Tachycardia

The AMETHIST phase 3 trial of venglustat in patients with GM2 gangliosidoses and related diseases: baseline characteristics (SSIEM 2023) - P3 | "Baseline characteristics in the secondary population (n=16) were mean age 12 years, juvenile/adolescent-onset GM2 (n=7), GM1 gangliosidosis (n=7), sialidosis type 1 (n=1), juvenile/adult galactosialidosis (n=1). AMETHIST is the first larger-scale clinical trial that will address relative benefits and risk of a treatment (venglustat) for late-onset GM2 gangliosidoses."

Clinical • P3 data • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. (PubMed, Lancet Neurol) - P2 | "In people with GBA1-associated Parkinson's disease in our study, venglustat had a satisfactory safety profile but showed no beneficial treatment effect compared with placebo. These findings indicate that glucosylceramide synthase inhibition with venglustat might not be a viable therapeutic approach for GBA1-associated Parkinson's disease."

Journal • P2 data • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease • GBA

The AMETHIST phase 3 trial of venglustat in patients with GM2 gangliosidoses and related diseases: baseline characteristics (WMS 2023) - No abstract available

Clinical • P3 data